BCR/abl

oncogene

Written by

The Information Architects of Encyclopaedia Britannica

Last updated

June 17, 2026

Quick Summary

The BCR-ABL oncogene is a fusion gene created by a chromosomal translocation, specifically the Philadelphia chromosome. This genetic abnormality occurs when a segment of chromosome 9, containing the c-ABL proto-oncogene, fuses with a segment of chromosome 22, known as the breakpoint cluster region (BCR).1

This fusion gene produces a hybrid protein that is a constitutively active tyrosine kinase. This means it constantly signals cancer cells to grow and divide, leading to the development of certain leukemias, most notably chronic myelogenous leukemia (CML). Targeted therapies, such as imatinib (Gleevec), have been developed to specifically inhibit this BCR-ABL protein, making CML a manageable chronic condition.21

Summary created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

2 Britannica Sources

Ask Britannica AI about this topic

Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.

human genetic disease
Genetics of cancer
…9, creating the dominant oncogene BCR/abl at the junction point. The specific function of the BCR/abl fusion protein is not entirely clear. Another example is Burkitt lymphoma, in which a rearrangement between chromosomes places the myc gene from chromosome 8 under the influence of regulatory sequences that normally control expression…
Read More
…9, creating the dominant oncogene BCR/abl at the junction point. The specific function of the BCR/abl fusion protein is not entirely clear. Another example is Burkitt lymphoma, in which a rearrangement between chromosomes places the myc gene from chromosome 8 under the influence of regulatory sequences that normally control expression…
Read More